Patent Eligibility For Cross-Species Gene Editing Innovations And Synthetic Biology.

20 Mar 2026 --
0 Comments

1. Understanding Patent Eligibility in Gene Editing and Synthetic Biology

Under 35 U.S.C. § 101, an invention must fall under one of these categories:

Process
Machine
Manufacture
Composition of matter

But courts have excluded laws of nature, natural phenomena, and abstract ideas. This creates complexity for synthetic biology and cross-species gene editing because:

Many inventions involve natural genes, proteins, or organisms.
The novelty often lies in engineering, modification, or novel combinations.
Mere discovery of a natural sequence or trait is not patentable.

Key principle: Patent claims must involve human-made modifications or inventive applications.

2. Key Case Laws

A. Diamond v. Chakrabarty (1980)

Facts: The Supreme Court addressed a genetically engineered bacterium capable of breaking down oil.
Holding: Genetically modified microorganisms are patentable because they are human-made, not naturally occurring.
Relevance: Cross-species gene editing—e.g., inserting genes from one species into another—is patentable if the resulting organism is non-naturally occurring.
Key point: Human-directed genetic engineering confers eligibility.

B. Association for Molecular Pathology v. Myriad Genetics (2013)

Facts: Myriad patented isolated BRCA1 and BRCA2 genes. The Supreme Court ruled that naturally occurring DNA sequences cannot be patented, but complementary DNA (cDNA) created synthetically is patentable.
Relevance: Simply transferring a gene between species (without modification) may not suffice. Engineered or synthetic sequences are patentable.
Key point: Modification or synthetic creation is essential.

C. Mayo Collaborative Services v. Prometheus Laboratories (2012)

Facts: Mayo patented a method of adjusting drug dosage based on metabolite levels. The Court ruled it applied a natural law using conventional steps, so it was not patentable.
Relevance: Gene editing methods that merely observe or use natural gene behavior without inventive techniques may fail §101 eligibility.
Key point: Innovative methods or applications beyond routine lab work are necessary.

D. Funk Brothers Seed Co. v. Kalo Inoculant Co. (1948)

Facts: The patent involved a mixture of bacteria that improved plant growth. It was rejected because each bacterium acted as it naturally did.
Relevance: Cross-species genetic constructs must produce a synergistic or novel effect, not merely combine genes without new function.
Key point: Functional novelty in combination is required.

E. In re Roslin Institute (2006)

Facts: Dolly the cloned sheep was not patentable because it was genetically identical to a naturally occurring sheep.
Relevance: Cloning or transferring genes without creating something significantly different from nature is not patentable. Cross-species gene editing must result in a distinct organism.
Key point: Replication of natural organisms does not meet §101.

F. Diamond v. Diehr (1981)

Facts: Patent involved curing rubber with a computer-controlled process. Court ruled it patentable because it applied a law of nature in a practical process.
Relevance: Gene editing methods integrated into a novel practical application (like producing a new therapeutic protein) may be patentable.
Key point: Practical application of a natural phenomenon can be eligible.

G. Ariosa Diagnostics, Inc. v. Sequenom, Inc. (2015)

Facts: Sequenom patented detection of fetal DNA in maternal blood. The Federal Circuit ruled the process applied a natural phenomenon with conventional steps and was not patentable.
Relevance: Using standard CRISPR or gene editing methods without inventive improvements may not be eligible.
Key point: Novelty in method or application is critical.

3. Practical Implications for Cross-Species Gene Editing & Synthetic Biology

Area	Patent Eligibility Considerations
Cross-Species Gene Editing	- Engineered organisms with genes from multiple species are patentable (Chakrabarty). - Natural gene transfers without modification are not (Myriad, Roslin). - Methods must involve inventive steps, not routine lab work (Mayo, Ariosa). - Must produce novel functional outcomes (Funk Brothers).
Synthetic Biology	- Synthetic DNA, RNA, proteins, or circuits are patentable (Myriad, Chakrabarty). - Computational or lab-designed organisms can be patentable if human-engineered (Diehr). - Mere discovery of natural sequences is insufficient.
Methods/Processes	- Processes applying natural phenomena in a practical and novel way are eligible (Diehr). - Processes that are routine, conventional, or purely analytical are not (Mayo, Ariosa).

4. Key Takeaways

Human-made innovation is essential: Engineered genes, synthetic constructs, or chimeric organisms are patentable.
Natural sequences or organisms alone are not patentable (Myriad, Roslin).
Process innovation matters: Simply using CRISPR or known lab methods is insufficient (Mayo, Ariosa).
Functional novelty: Cross-species organisms must produce new capabilities or effects (Funk Brothers).
Practical applications strengthen claims: Integration into manufacturing, therapeutics, or industrial processes helps eligibility (Diehr).